tbuckley/cabot-search huggingface dataset:
Abstract 2751: Preoperative Cardiothoracic Computed Tomographic Angiography is Associated with Increased Adoption of Preventive Surgical Techniques in Patients Undergoing Redo Open Heart Surgery after Prior Coronary Artery Bypass Grafting
Authors: Apur R Kamdar, Telly A Meadows, Eiran Z Gorodeski, Ronan J Curtin, Eric E Roselli, Joseph Sabik, Paul Schoenhagen, Bruce W Lytle, Scott D Flamm, Milind Y Desai
Journal: Circulation (2007)

Introduction: Redo cardiothoracic surgery (CTS) is associated with increased morbidity and mortality, compared to first-time CTS. Multi-detector computed tomography angiography (MDCTA) reliably delineates the course of previous coronary artery bypass grafts (CABG) and proximity of mediastinal structures to chest wall. We sought to determine if high risk preoperative MDCTA findings impacted use of preventive surgical strategies in patients with prior CABG undergoing re-CTS. Methods: We studied 167 patients (mean age 69 ± 9 years, 79% men) with prior CABG referred for re-CTS who underwent contrast-enhanced MDCTA (16 – 64 MDCT, 2 mm slice thickness) to assess CABG location and relationship of aorta/right ventricle (RV) to chest wall. Demographic, laboratory, and clinical data were used to determine the Higgins preoperative risk score. Prevalence of high risk MDCTA findings, use of preventive surgical strategies, frequency of severe intraoperative bleeding and postoperative mortality were recorded. Results: Mean preoperative risk score was high (7.5 ± 3) and 49% patients underwent combined redo CABG plus valve surgery. Incidences of 2 nd , 3 rd and 4 th operations were 78%, 19% and 3%, respectively. High-risk CT findings were as follows: adherence/ proximity (≤ 1 cm) of RV/aorta to chest wall (24%) or bypass graft crossing midline (≤ 1 cm antero-posteriorly) (38%). Preventive surgical strategies included: surgery cancelled (4%), non-midline incision (8%), deep hypothermic circulatory arrest (5%), initiation of peripheral cardiopulmonary bypass (11%), and extrathoracic vascular exposure prior to incision (53%). These surgical strategies were used at a significantly higher frequency in patients with high risk MDCTA findings compared to those without (88% vs. 28%, p&lt;0.0001). After adjustment for multiple clinical variables, only high risk MDCTA finding was significantly associated with operative changes (OR=16 [95% CI 7–36], p&lt;0.001). Frequency of severe bleeding, graft injuries, and 1 month mortality were 3%, 5% and 3 %, respectively. Conclusions: In high risk re-CTS patients with prior CABG, use of preoperative MDCTA plays a significant role in planning and performance. Impact of preoperative MDCTA on outcomes requires further evaluation.
Stat3 as a correlate of distant metastasis in RTOG 86–10
Authors: J. F. Torres-Roca, M. Desilvio, L. B. Mora-Diaz, E. Hammond, N. Ahmad, R. Jove, J. Forman, R. J. Lee, H. Sandler, A. Pollack
Journal: Journal of Clinical Oncology (2005)

4656 Background: Stat3 participates in the regulation of cellular growth, survival and oncogenesis. We evaluated Stat3 as a prognostic factor in prostate cancer, by determining Stat3 activity in a cohort of patients treated on RTOG 86–10, a phase III trial that randomized prostate cancer patients between RT alone and RT and short-term androgen blockade. Methods: 62 patients with sufficient tissue were stained with phospho-Stat3 antibody. Stat3 activity was quantified manually and with an image analysis system (ACIS, Chromavision, San Juan Capistrano, CA). Nuclear Stat3 staining was considered positive. The results were correlated with overall mortality (OM), cause specific mortality (CSM), local progression (LP) and distant metastasis (DM) rate. Statistical comparisons were carried out using the chi-square test and Cox proportional hazards models. Stat3 activity quantified using the ACIS Index (percentage positive) was modeled as a continuous variable. ACIS Index cut-points were also tested (the median, the 25% and 75% Quartile) using univariate models of all four endpoints. Estimates for OM and CSM were calculated using the Kaplan-Meier method. The cumulative incidence method was used to estimate LP and DM failure rates. Results: There was no significant difference in the distribution of clinical characteristics and assigned treatment between the patients available for Stat3 analysis (Stat3 cohort) and the others in RTOG 86–10 (n=394). However, the Stat3 cohort had a higher risk for development of DM (RR=1.53, p=0.02) and worse CSM (p=0.04). When treated as a continuous variable, Stat3 activity, as determined by the ACIS-Index, was correlated with the development of DM (RR=0.81, p=0.04) but not with OM, CSM or LP. Similar results were obtained when the data were dichotomized (ACIS Index, ≤29% vs. >29%, 5-yr DM Rate 53.2% vs. 26.7%, p=0.07). Finally, there was no difference in the distribution of clinical and prognostic variables between patients with Stat3-Index > 29% and those with Stat3-Index ≤ 29%. Conclusions: Stat3 activity is correlated with the development of distant metastasis in prostate cancer. This marker should be further evaluated in a larger cohort of patients. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration RTOG
The Ulcer Diet Cook Book.
Authors: Harold Irving Rubin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma
Authors: C. K. Augustine, S. Jung, A. Potti, I. Sohn, J. S. Yoo, P. Zipfel, J. Olson, F. Ali-Osman, J. R. Nevins, D. S. Tyler
Journal: Journal of Clinical Oncology (2008)

9077 Background: In an era of targeted therapeutics biopsies are increasingly used to personalize cancer treatment. The utility of a single biopsy from a melanoma patient with multifocal disease to define the characteristics of that patient’s tumor is unclear. The aim of this study was to evaluate the genetic and molecular relationship of multifocal lesions and determine if one lesion is representative of residual tumor burden. Methods: Expression across 38k genes was measured using GeneChip microarrays. Binary regression, unsupervised hierarchical clustering, principal component analysis (PCA) and analysis of variance (ANOVA) were used to evaluate the patterns of expression across lesions. Predictions of sensitivity to chemotherapy and oncogenic signaling pathway activation were evaluated using signatures derived from the NCI-60 panel of cancer cell lines. Results: 43 in-transit lesions were obtained from 17 different patients with multifocal extremity melanoma. PCA and unsupervised hierarchical clustering showed distinctly different patterns of gene expression across patients but significantly correlated (average r = 0.979) patterns within a patient. Sensitivity to melphalan and temozolomide was evaluated using defined gene signatures. Predictions across multifocal lesions were significantly correlated within an individual patient (ANOVA p-value: <0.001) and significantly different across patients (p<0.05). Similarly, predicted patterns of gene expression across 6 signaling pathways (Src, PI3K, Ras, Myc, E2F and β-catenin) were significantly correlated within but not across patients (p<0.0001 to 0.0006). Conclusions: Individual melanoma tumor nodules in patients with multifocal disease are similar and can be used to predict chemosensitivity, genetically characterize a patient’s disease and evaluate the activation status of oncogenic signaling pathways. These findings will facilitate the application of microarray-based gene expression profiling in clinical melanoma trials, allowing for a more rational way to identify candidates for specific targeted therapies, and demonstrate that single biopsies obtained for correlative science studies are representative of residual tumor burden. No significant financial relationships to disclose.
Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers
Authors: S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, G. W. Sledge
Journal: Journal of Clinical Oncology (2009)

549 Background: Because male breast cancer (BC) is rare, there is little known about the disease and treatment is extrapolated from female BC. Newer molecular technologies have not been used to profile male BC. We report here a study of quantitative gene expression by gender status in tumor specimens submitted for Recurrence Score testing. Methods: All estrogen receptor positive tumor specimens successfully examined in the Genomic Health laboratory from June 2004 through December 2008 were included. Quantitative expression for each gene was measured by the 21 gene oncotype DX assay on a scale from 0 to 15 (relative to reference genes), where a one unit increment is associated with a 2-fold change in expression. Results: There were 347 male and 82,434 female BCs. The males were older (mean age 63.8 vs 57.4 yrs). Standard histopathology was similar, although slightly more male BCs were ductal (83% vs 78%). Like female BC, there was a wide variation in gene expression in male BC. The distribution of RS in males and females was similar - RS mean (±SD) 18.1 (±11.2) in males and 19.1 (±10.2) in females (p = NS). The proportion of tumors with RS &lt;18, 18 - 30, and ≥ 31 was 53.6%, 35.2%, and 11.2% in males and 53.4%, 36.3%, and 10.3% in females. Although the patterns of expression of the Oncotype DX genes were more similar than different in males and females some differences were notable. Mean expression of ER, PR, and SCUBE2 were 0.5 units higher in males. Mean expression of the proliferation genes, Ki-67, MYBL2, Survivin, Cyclin B1, and STK15, were 0.5 units higher in males. Mean expression of STMY3 was 0.9 units higher in males. Of note, whereas the level of quantitative ER significantly increased with increasing patient age in females (0.4 units per decade), little increase was observed in males (&lt;0.1 units per decade). Conclusions: This large genomic study of male BC reveals a heterogeneous biology as measured by the standardized quantitative oncotype DX breast cancer assay, similar to that observed in female BC. Some differences, which may reflect the differences in hormone biology between males and females, were noted and deserve further study. [Table: see text]
Abstract 2721: Linkage of Left Ventricular Outflow Tract Obstruction to Xq28 in 3 French-Canadian Pedigrees
Authors: Sylvie Provost, Philippe Chetaille, Ana Siles, Maryse Thibeault, Nathalie Bureau, Kathleen Riopel, Jocelyne Mercier, Virginie Poisson, Séverine Leclerc, Michelle Jaeggi, Christine Houde, Joaquim Miro, Jean-Luc Bigras, Marie-Pierre Dubé, Andrea Richter, Gregor Andelfinger
Journal: Circulation (2007)

BACKGROUND: Statistical genetic analysis of cohorts with left ventricular outflow tract obstruction (LVOTO) shows high heritability of such lesions. We have identified three X-linked French-Canadian pedigrees with a total of 54 family members with multiple cases of LVOTO and septal defects. AIMS: The aim of this study was to evaluate the three pedigrees with LVOTO and septal defects for genetic linkage to the X chromosome. METHODS: Detailed family history, physical exam, ECG, echocardiography and chart review was performed. Informed consent was obtained from all participants. Genomic DNA was isolated from peripheral blood samples. Twenty-four STR markers from the X chromosome were genotyped. We used a dominant genetic model with the following penetrances: 0.99 for homozygous women, 0.75 for heterozygous women, 0.99 for hemizygous men. Phenocopy rate was set to 0.01 and disease allele frequency to 0.001. Reference allele frequencies from the Quebec population were used. Analyses were performed with MLINK and MERLIN. RESULTS: Sixteen family members were affected (13 males, 3 females). Predominant lesions were atrial (n = 5) and ventricular (n = 6) septal defects, coarctation (n = 4) and aortic lesions (stenosis (n = 4), bicuspid/abnormal aortic valve (n = 6)), as well as mitral valve lesions (n = 4). Males had a high incidence of supraventricular arrhythmias postoperatively (4 with atrial flutter/fibrillation, one with ICD implantation). LOD scores above 2 were obtained in parametric two-point linkage analysis for 3 markers in the Xq28 region. Multipoint non-parametric linkage analysis confirmed these results with a NPL score of 9.1 (P &lt; .00001) over a STR marker in intron 13 of the F8C gene. Haplotype analysis allowed the definition of a candidate interval flanked by marker DXS8069 spanning to the telomeric end of Xq. CONCLUSIONS: By analysing 3 multi-generation French-Canadian pedigrees, we mapped a syndrome of LVOTO and septal defects to the Xq28 region. Further work will refine our candidate region with dense SNP coverage to search for a shared haplotype identical by descent between the three French Canadian families, to complete the sequencing of candidate genes including FLNA, and to search for a possible founder effect in our population.
Unhappy Marriage and Divorce: A Study of Neurotic Choice of Marriage Partners
Authors: Edmund Bergler, A. A. Brill
Journal: JAMA (1946)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A feasibility/phase II study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer (CRC) (OGSG 0304)
Authors: Y. Miyake, H. Ishida, M. Fukunaga, T. Kato, Y. Watanabe, H. Takemoto, H. Furukawa
Journal: Journal of Clinical Oncology (2008)

15086 Background: This is a feasibility/phase II trial of TEGAFIRI with maximum dose confirmed in Japan. Objectives: To document the toxicity and define the objective response rate; and determine progression free and overall survival. Methods: Pts with advanced or metastatic CRC received: UFT 300mg/m2, LV 75 mg/body, CPT-11 150mg/m2 (UFT and LV given on d1- 14, CPT-11 on d1, every 3 wks). Eligibility: ECOG PS 0–1, adequate bone marrow/liver function, serum creatinine level < institutional normal value. Results: 18 pts enrolled, 17 evaluable for toxicity and response; 1 patients recalled chemotherapy upon registration. Characteristics: 61% male, median age 63.5 yrs (51–71). 72% PS 0, 78% 1st line. 186 cycles have been delivered. The common grade 3 to 4 toxicities were neutropenia (35.3%), leukopenia (29.4%), diarrhea (5.9%), anorexia (5.9%), vomiting (5.9%) and dizziness (5.9%). There were no episode of febrile neutropenia. No death occurred on treatment: Overall RR was 41% (7/17: 1 CR+ 6 PR). Median survival is 511+ days. One- year survival rate is 65+%. Conclusion: The combination therapy of UFT/LV and irinotecan (TEGAFIRI) for patients with advanced or metastatic CRC seems to be effective and well tolerated in Japan. The survival period is being assessed and updated data will be present at the meeting. No significant financial relationships to disclose.
Philosophy of Science. The Delaware Seminar.
Authors: Bernard H. Baumrin
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
麻疹在发展中国家的状况 维生素A和抗生素可预防并发症，但疫苗仍为首选措施
Authors: Neal, Halsey, 吕玮（译）
Journal: BMJ (2007)

在许多国家，由于麻疹疫苗的广泛应用以及临床水平的提高和社会经济条件的改善，麻疹的死亡率明显下降。然而，麻疹仍然是全球发病率和死亡率较高的重要疾病之一，近年报道非洲某些国家儿童麻疹的死亡率可高达9．7％。肺炎是麻疹导致死亡的最常见原因，可以是由病毒引起，也可以是由继发的单纯疱疹病毒、腺病毒或细菌感染引起。在发展中国家，增加肺炎和其他并发症的因素包括感染时年龄小，居住拥挤，营养不良，特别是维生素A缺乏。
SKIN-GRAFTING FROM THE DOG.
Authors: Elroy C. Jensen
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Culdoscopy: A New Technic in Gynecologic and Obstetric Diagnosis.
Authors: Albert Decker, Richard W. TeLinde
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TPF induction therapy with radioimmunochemotherapy for the treatment of head and neck cancer
Authors: W. Jordan, I. Wildfang, H. Welkoborsky, J. Borghardt, H. Zakaria, B. Tschechne
Journal: Journal of Clinical Oncology (2009)

e17021 Background: As of the good data for radiotherapy with cetuximab and the promising results of an induction chemotherapy containing docetaxel we developed a combination of these regimes. This retrospective analysis evaluates the safety and feasibility of a TPF induction therapy under pegfilgrastim protection with a subsequent concomitant RT immunochemotherapy using cetuximab. Methods: 64 patients (8 female/56 male) with advanced (mostly metastatic; T3/T4) head &amp; neck cancer were treated. Patients were between 39 and 78 years old (median 61), ECOG between 1 and 3. Induction therapy consisted of three 21-day-cycles TPF (75 mg/m2 docetaxel d1; 35 mg/m2 cisplatin d1,2; 750 mg/m2 5-FU d1–5) and on d7 a protective dose of 6 mg pegfilgrastim. Before and after induction therapy PET-CT was used to evaluate response. PET-CT allowed best possible RT-planning with best adapted field margins. Subsequent radioimmunochemotherapy consisted of 400 mg/m2 cetuximab on day 1 (initial dose) and seven weekly cycles of 250 mg/m2 cetuximab and 40 mg/abs cisplatin on day 1. Radiotherapy on d1–5/; 1,8 Gy/day for a median dose 61,2 Gy (59,4 - 70,2 Gy). During the whole treatment CRP was monitored twice weekly and if necessary antibiotics were administered iv. Results: All 64 patients were evaluated after therapy completion. One death occured which was not treatment related (myocard infarct). Five patients decided not to complete the treatment. The response rates were: CR 56% (36), PR 31% (20), SD 11% (7), and PD 2% (1). 10 grade 3/4 toxicities had to be observed during radioimmunotherapy (skin rash, diarrhoe). All toxicities were reversible. In five patients therapy had to be interrupted for two weeks (skin rash). Karnofsky index could be kept stable and in some cases even improved. Conclusions: The new regimen is safe, shows great promise and deserves further development. PET-CT as a diagnostic tool, pegfilgrastim as a myeloprotective agent and docetaxel/cetuximab make a good combination. Especially during the induction therapy QoL is drastically improved. No significant financial relationships to disclose.